Laura Illingworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Illingworth has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Gloria Kayani
Thrombosis Research Institute, London, England
3 shared publicationsKaren S. Pieper
Thrombosis Research Institute, London, England
3 shared publicationsA. John Camm
St George's University of London, London, England
2 shared publicationsAjay K. Kakkar
University College London, London, United Kingdom
2 shared publicationsAlexander G. G. Turpie
McMaster University, Hamilton, Ontario, Canada
2 shared publicationsDavid A. Fitzmaurice
Warwick Medical School, University of Warwick, Coventry, England
2 shared publications
Latest Publications
- Open Access
- 1 June 2019
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 4 (6) , 526-548
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation
Congestive heart failure (CHF) is commonly associated with atrial fibrillation (AF), and their combined presentation confers a worse prognosis than either condition alone.1 Treatment of both conditions implies use of specific drugs for CHF plus antithrombotic agents for stroke prevention. In addition, management strategies and outcomes may be affected by the etiology of CHF, namely ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM) because the prescription of antithrombotic therapies might be different and could affect prognosis in terms of death, stroke/systemic embolism (SE), and bleeding.2,3 The aim of our study was to assess the treatment strategies in terms of antithrombotic and CHF therapies and 1-year clinical outcomes in patients with newly diagnosed AF and concomitant CHF stratified by etiology (ICM vs NICM) enrolled in the Global Anticoagulant Registry in the Field–Atrial Fibrillation (GARFIELD-AF) registry.
- 1 June 2019
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 4 (6) , 526-548
Open AccessAnalysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation
Congestive heart failure (CHF) is commonly associated with atrial fibrillation (AF), and their combined presentation confers a worse prognosis than either condition alone.1 Treatment of both conditions implies use of specific drugs for CHF plus antithrombotic agents for stroke prevention. In addition, management strategies and outcomes may be affected by the etiology of CHF, namely ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM) because the prescription of antithrombotic therapies might be different and could affect prognosis in terms of death, stroke/systemic embolism (SE), and bleeding.2,3 The aim of our study was to assess the treatment strategies in terms of antithrombotic and CHF therapies and 1-year clinical outcomes in patients with newly diagnosed AF and concomitant CHF stratified by etiology (ICM vs NICM) enrolled in the Global Anticoagulant Registry in the Field–Atrial Fibrillation (GARFIELD-AF) registry.
- Open Access
- 15 March 2019
- Published by Wiley in Clinical Cardiology
- Vol. 42 (5) , 553-560
Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry
Background: Atrial fibrillation (AF) is an important preventable cause of stroke. Anticoagulation (AC) therapy can reduce this risk. However, prescribing patterns and outcomes in patients with non‐valvular AF (NVAF) from Latin American countries are poorly described.Methods: Using data from the Global Anticoagulant Registry in the FIELD‐AF (GARFIELD‐AF), we examined the stroke prevention strategies and the 1‐year outcomes in patients from four Latin American countries: Argentina, Brazil, Chile, and Mexico.Results: A total of 4162 patients (2010‐2014) were included in this analysis. At the time of AF diagnosis, 39.9% of patients were prescribed vitamin K antagonists (VKA) ± antiplatelet (AP) therapy, 21.8% non‐VKA oral anticoagulant (NOAC) ± AP, 24.1% AP only and 14.1% no antithrombotic treatment. The proportion of moderate‐high risk patients receiving no AC therapy at participating centers was highest in Mexico (46.4%) and lowest in Chile (14.3%). During 1‐year follow‐up, the rates of all‐cause mortality, stroke/SE and major bleeding were: 5.77 (95% CI) (5.06‐6.56), 1.58 (1.23‐2.02), and 0.99 (0.72‐1.36) and per 100 person‐years, respectively, which are higher than the global rates across all countries in GARFIELD‐AF. Unadjusted rates of all‐cause mortality were highest in Argentina, 6.95 (5.43‐8.90), and lowest in Chile, 4.01 (2.92‐5.52).Conclusions: GARFIELD‐AF results describes the marked variation in the baseline characteristics and patterns of antithrombotic treatments in patients with NVAF in four Latin American countries. Over one‐third of patients with a moderate‐to‐high risk of stroke received no AC therapy, highlighting the need for improved management of patients according to national guideline.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
- 15 March 2019
- Published by Wiley in Clinical Cardiology
- Vol. 42 (5) , 553-560
Open AccessStroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry
Background: Atrial fibrillation (AF) is an important preventable cause of stroke. Anticoagulation (AC) therapy can reduce this risk. However, prescribing patterns and outcomes in patients with non‐valvular AF (NVAF) from Latin American countries are poorly described.Methods: Using data from the Global Anticoagulant Registry in the FIELD‐AF (GARFIELD‐AF), we examined the stroke prevention strategies and the 1‐year outcomes in patients from four Latin American countries: Argentina, Brazil, Chile, and Mexico.Results: A total of 4162 patients (2010‐2014) were included in this analysis. At the time of AF diagnosis, 39.9% of patients were prescribed vitamin K antagonists (VKA) ± antiplatelet (AP) therapy, 21.8% non‐VKA oral anticoagulant (NOAC) ± AP, 24.1% AP only and 14.1% no antithrombotic treatment. The proportion of moderate‐high risk patients receiving no AC therapy at participating centers was highest in Mexico (46.4%) and lowest in Chile (14.3%). During 1‐year follow‐up, the rates of all‐cause mortality, stroke/SE and major bleeding were: 5.77 (95% CI) (5.06‐6.56), 1.58 (1.23‐2.02), and 0.99 (0.72‐1.36) and per 100 person‐years, respectively, which are higher than the global rates across all countries in GARFIELD‐AF. Unadjusted rates of all‐cause mortality were highest in Argentina, 6.95 (5.43‐8.90), and lowest in Chile, 4.01 (2.92‐5.52).Conclusions: GARFIELD‐AF results describes the marked variation in the baseline characteristics and patterns of antithrombotic treatments in patients with NVAF in four Latin American countries. Over one‐third of patients with a moderate‐to‐high risk of stroke received no AC therapy, highlighting the need for improved management of patients according to national guideline.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
- Open Access
- 5 February 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (3) , e010510
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
Background: Using data from the GARFIELD ‐ AF (Global Anticoagulant Registry in the FIELD –Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results: GARFIELD ‐ AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA 2 DS 2 ‐ VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P =0.001). Conclusions: In GARFIELD ‐ AF , moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.
- 5 February 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (3) , e010510
Open AccessManagement and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
Background: Using data from the GARFIELD ‐ AF (Global Anticoagulant Registry in the FIELD –Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results: GARFIELD ‐ AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA 2 DS 2 ‐ VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P =0.001). Conclusions: In GARFIELD ‐ AF , moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.